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Summary. Background: As the placental vessels are depend-
ent on the normal balance of procoagulant and anticoagulant
mechanisms, inherited thrombophilia may be associated with
fetal loss. Objectives: We performed a prospective study to
investigate the relation between inherited thrombophilia and
fetal loss, and the inﬂuence of thromboprophylaxis on preg-
nancy outcome.Patients andmethods: Womenwere enrolled in
theEuropeanProspectiveCohort onThrombophilia (EPCOT).
These included women with factor (F)V Leiden or a deﬁciency
of antithrombin, protein C or protein S. Controls were partners
or acquaintances of thrombophilic individuals. A total of 191
women (131 with thrombophilia, 60 controls) had a pregnancy
outcome during prospective follow-up. Risk of fetal loss and
eﬀect of thromboprophylaxis were estimated by frequency
calculation and Cox regression modelling. Results: The risk of
fetal loss appeared slightly increased in women with thrombo-
philia without a previous history of fetal loss who did not use
any anticoagulants during pregnancy (7/39 vs. 7/51; relative risk
1.4; 95% conﬁdence interval 0.4, 4.7). Per type of defect the
relative risk varied onlyminimally from1.4 forFVLeiden to 1.6
for antithrombin deﬁciency compared with control women.
Prophylactic anticoagulant treatment during pregnancy in 83
women with thrombophilia diﬀered greatly in type, dose and
duration, precluding solid conclusions on the eﬀect of throm-
boprophylaxis on fetal loss. No clear beneﬁt of anticoagulant
prophylaxis was apparent. Conclusions: Women with throm-
bophilia appear to have an increased risk of fetal loss, although
the likelihood of a positive outcome is high in both womenwith
thrombophilia and in controls.
Keywords: fetal loss, thrombophilia, thromboprophylaxis.
Introduction
Thrombotic risk is increased in normal pregnancy, which may
be the result of an evolutionary advantage associated with
reduced blood loss after delivery and placenta separation. This
risk is further enhanced in women with congenital or acquired
thrombophilia [1]. In addition, it has been shown that
postpartum blood loss is reduced in women with factor (F)V
Leiden [2,3]. As an adequate placental circulation is dependent
on the normal balance of procoagulant and anticoagulant
mechanisms, inherited thrombophilia may be associated with
fetal loss.
In a retrospective analysis [4] of women participating in the
European Prospective Cohort on Thrombophilia (EPCOT)
study, we observed a slightly increased risk of fetal loss in
women with hereditary thrombophilia [168/571 vs. 93/395;
odds ratio 1.35; 95% conﬁdence interval (CI) 1.10, 1.82].
Several other studies have conﬁrmed an association between
thrombophilia and fetal loss [5–18].
Subsequent to our retrospective baseline analysis [4], we
followed the women in the EPCOT cohort prospectively to
investigate the relation between fetal loss and inherited
thrombophilia. The prospective study design allowed us to
study women in a well-deﬁned and homogeneous time frame
with homogeneous general conditions, as well as to reduce
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recall bias. To prevent venous thromboembolism during
pregnancy, pregnant women with inherited thrombophilia
often receive thromboprophylaxis, such as heparin, oral
anticoagulants or aspirin. This policy is a matter of contro-
versy, and therefore applied in some centers, but not in all. As
thromboprophylaxis could prevent fetal loss by preventing
thrombosis in fetal placental vessels, we evaluated the effect of
anticoagulants during pregnancy on pregnancy outcome.
Subjects and methods
Subjects
Thewomen described in this studywere enrolled in the EPCOT
study between March 1994 and September 1997 and subse-
quently followed prospectively. The primary aim of the
EPCOT study was to establish the risk of thrombosis in
individuals with inherited thrombophilia. Nine centers in eight
countries (Austria, France, Germany, UK, Italy, the Nether-
lands, Spain, and Sweden) participated and followed all
consenting individuals with a deﬁciency of natural coagulation
inhibitors (antithrombin, protein C, protein S), resistance to
activated protein C due to FV Leiden, or a combination of
these defects. As controls, partners or, if there were none,
friends or acquaintances of the thrombophilic participants were
included. Data were collected at baseline, and annually at
follow-up by questionnaire, telephone or personal interview
until January 2001. For follow-up data, information on the
occurrence of risk situations or events was screened by
questionnaire or telephone, and, when reported, further
information was obtained from a physician. The data recorded
at baseline included general demographic information, history
with regard to thrombosis, current medication, obstetric
history, family information and (only for thrombophilic
individuals) details on type and subtype of thrombophilia.
The data recorded at follow-up included the number of births,
pregnancies and miscarriages, current medication and occur-
rence of risk situations for thrombosis. While there were no
exclusion criteria for thrombophilic individuals, controls were
excluded when they were blood relatives of an individual with
an inherited thrombotic defect or were known to have heritable
thrombophilia.
For assessing the risk of fetal loss, we selected from the
participating women those aged between 13 and 45, with at
least one pregnancy ending in livebirth or fetal loss during
prospective follow-up. We excluded women with only elective
pregnancy terminations. Partners of men in the cohort or
female acquaintances of thrombophilic individuals were inclu-
ded as controls.
Analysis
Only the ﬁrst pregnancy during prospective follow-up (regard-
less of previous pregnancies reported before inclusion) was
considered for the analysis. Riskwas expressed as the frequency
of fetal loss, i.e. the proportion of all ﬁrst pregnancies ending in
fetal loss. Fetal loss was deﬁned as any loss during pregnancy
independent of time of occurrence.
In the analysis aimed at assessing the risk of fetal loss
associated with thrombophilia, we excluded women who used
thromboprophylaxis during their ﬁrst pregnancy during pros-
pective follow-up. The effect of anticoagulants on pregnancy
outcome was analyzed by comparing the risk of fetal loss
between those with anticoagulants (heparin, oral anticoagu-
lants) during the ﬁrst pregnancy and those without thrombo-
prophylaxis during the ﬁrst pregnancy since study entry. Both
calculations were performed per pregnant woman (i.e. not per
pregnancy) by Cox regression analysis with fetal loss as the
outcome (dependent) variable and presence of thrombophilia
or use of prophylaxis as covariate (independent variable).
Follow-up time was the number of weeks of pregnancy. To
adjust for regional effects and the inﬂuence of the number of
previous pregnancies, center (as stratum) and the total number
of pregnancies (as independent variable) were added in the Cox
regression model. We also considered the effect of a history of
fetal loss or venous thrombosis and the inﬂuence of gestation at
age ‡35 years.
Results
A total of 1573 women were enrolled in the cohort (988 with
thrombophilia, 585 controls), of whom 191 completed at least
one pregnancy during prospective follow-up (131 with throm-
bophilia, 60 controls). Of the controls, 37 (62%) were female
partners and 23 (38%) were friends of participants with
thrombophilia. Among the 131 thrombophilic women, 83
(63%) used thromboprophylaxis during the ﬁrst pregnancy in
prospective follow-up. None of the controls used thrombo-
prophylaxis during pregnancy. The main characteristics are
shown in Table 1. Most women had their ﬁrst fetal loss during
prospective follow-up. A history of venous thrombosis was
present predominantly among womenwith thrombophilia who
used thromboprophylaxis during the ﬁrst pregnancy since
study entry.
Fetal loss
A total of 108 women (48 with thrombophilia, 60 controls) did
not use thromboprophylaxis during the ﬁrst pregnancy since
study entry. Fetal loss occurred among 10 of the 48 women
with thrombophilia (21%), and among 10 of the 60 control
women (17%). The relative risk for fetal loss associated with
thrombophilia was 1.4 (95% CI 0.5, 3.8), adjusted for center
and the number of pregnancies. In both thrombophilic women
and controls, the risk of fetal loss was higher if they had a
history of fetal loss [3/9 (33%) in both women with thrombo-
philia and controls] or when women were ‡35 years old at
gestation [4/9 (44%) in women with thrombophilia, 3/9 (33%)
in controls] (Table 2). A history of venous thrombosis (only
present in women with thrombophilia) did not affect the risk of
fetal loss. Further adjustment for a history of fetal loss and age
at gestation (<35 vs. ‡35) resulted in a relative risk of 1.7 (95%
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CI 0.6, 4.6) for thrombophilic women vs. controls. Exclusion of
women with a history of fetal loss resulted in a relative risk of
1.4 (95% CI 0.4, 4.7) for thrombophilia carriers vs. pregnant
control women, adjusted for age at pregnancy, regional effects
and number of total pregnancies. Per type of defect, the relative
risk, adjusted for age at gestation and number of previous
pregnancies, varied little: 1.4 (95% CI 0.3, 5.5) for the FV
Leiden mutation, 1.5 (95% CI 0.2, 12.9) for protein S
deﬁciency, 1.5 (95% CI 0.3, 7.9) for protein C deﬁciency and
1.6 (0.3, 14.0) for antithrombin deﬁciency. Of all thrombophilic
women and controls with no previous pregnancies before
prospective follow-up, two of the 18 (11%) thrombophilic
women and ﬁve of the 26 (19%) controls experienced fetal loss.
The mean number of weeks at which fetal loss took place
was week 9 (range 4–18) in women with thrombophilia and
week 9 (range 4–17) in controls. Eight women with thrombo-
philia (80%) and nine controls (90%) experienced a ﬁrst-
trimester fetal loss (between week 0 and 12) with a relative risk
for ﬁrst-trimester fetal losses of 1.6 (95% CI 0.5, 4.7) adjusted
for age at pregnancy, regional effects and number of total
pregnancies. The frequency of caesarian sections was the same
for women with thrombophilia (21%) and control women
(20%).
For 91 of the 131 pregnant women with thrombophilia, we
had information on genotyping for the prothrombin G20210A
mutation. None of the 12 women with this mutation (11
heterozygous, one homozygous) experienced fetal loss. So,
among a total of 14 women with combined defects, no
pregnancy loss was observed.
Most of the controls were partners of men with a thrombotic
defect. We assessed the effect of paternal thrombophilia on
pregnancy outcome, and found none: the relative risk of fetal
loss for partner controls vs. friend controls was 0.4 (95% CI
0.1, 2.2), adjusted for center, age at gestation, number of
pregnancies and history of fetal loss.
Effect of using anticoagulants
A total of 83 women with thrombophilia received thrombo-
prophylaxis, i.e. heparin (n ¼ 77), oral anticoagulants (n ¼ 5)
or aspirin (n ¼ 1), at some point during the ﬁrst pregnancy in
prospective follow-up. The frequency of thromboprophylaxis
varied among centers between 31% and 93% of all pregnant
women with thrombophilia. The percentage of women receiv-
ing thromboprophylaxis was high for women with antithrom-
bin deﬁciency or combined defects, respectively 82% and 83%,
compared with 61% of the women with protein C deﬁciency,
70% of the women with protein S deﬁciency, and 42% of the
women with the FV Leiden mutation. The indication for
thromboprophylactic treatment during pregnancy was known
for 71 women (86%), of whom only 20 women (28%) received
thromboprophylaxis to prevent fetal loss. The type, dose and
duration of anticoagulant treatment therefore ranged greatly
among the womenwith thrombophilia. Among 21womenwith
thrombophilia who used heparin or oral anticoagulants before
week 5 of the pregnancy until the end of the pregnancy, ﬁve
(24%) experienced fetal loss with an unadjusted relative risk of
fetal loss associated with thromboprophylaxis of 1.1 (95% CI
Table 2 Fetal loss in women without thromboprophylaxis (heparin, oral anticoagulants, aspirin) during pregnancy
Women with thrombophilia
Controls
Single defects
PC PS AT FVL*
Combined
defects Total
Pregnant, N 13 7 5 21 2 48 60
Fetal loss, N 4 2 1 3 0 10 (21%) 10 (17%)
History of fetal loss, N 2 1 0 5 1 9 9
Fetal loss, N 2 1 0 0 0 3 (33%) 3 (33%)
Age at pregnancy ‡35, N 1 2 1 4 1 9 9
Fetal loss, N 1 1 0 2 0 4 (44%) 3 (33%)
PC, Protein C deﬁciency; PS, protein S deﬁciency; AT, antithrombin deﬁciency; FVL, factor V Leiden mutation. *Only heterozygotes. Both had
protein S deﬁciency and the factor V Leiden mutation.
Table 1 Inclusion characteristics of women pregnant during prospective follow-up
Women with thrombophilia (N ¼ 131)
Controls (n ¼ 60)
First pregnancy after study
entry without thromboprophylaxis
(N ¼ 48)
First pregnancy after study entry
with thromboprophylaxis
(N ¼ 83)
Age at inclusion, mean (range) 28.7 (19–41) 29.1 (16–39) 28.7 (13–38)
History of pregnancies, N (%)* 30 (63) 48 (58) 34 (57)
History of fetal loss, N (%) 9 (19) 12 (14) 9 (15)
History of VT, N (%) 9 (19) 43 (52) 0 (0)
VT, Venous thrombosis. *Range of number of pregnancies was 1–7 in women with thrombophilia and 1–5 in controls. All women had one
previous fetal loss.
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0.4, 3.3), and a relative risk adjusted for center, total number of
pregnancies, history of fetal loss and age at gestation of 0.7
(95% CI 0.2, 3.2). The mean pregnancy duration until
miscarriage in these women was 13 weeks (range 6–29).
Discussion
Earlier retrospective data in the EPCOT study showed that the
risk of fetal loss was increased in women with thrombophilia
(168/571 vs. 93/395; odds ratio 1.35; 95%CI 1.01, 1.82) [4]. We
found a similar risk during this prospective follow-up study of
1.4 (95% CI 0.4, 4.7) for thrombophilic women without a
previous history of fetal loss and who did not use any
anticoagulants during pregnancy versus controls, adjusted for
age, number of previous pregnancies and regional effects. Even
though the present study in itself could not exclude the absence
of an increased risk with a 95% CI from 0.4 to 4.7, this
statistical uncertainty is likely to be the result of the smaller
number of pregnancies compared with the retrospective
analysis, and the results of both analyses are in agreement. A
major difference between the prospective and retrospective
analyses is that the odds ratio in the retrospective analysis was
higher for stillbirth than for miscarriage, whereas none of the
women experienced a stillbirth in the prospective analysis. This
difference is probably the result of the lower number of
individuals followed in the prospective study; 4% of the
thrombophilic women experienced a stillbirth in the retrospec-
tive study and 27% a miscarriage, so if we take these
percentages (which are based on a longer follow-up period),
we would expect two stillbirths and 13 miscarriages in the 48
women without use of anticoagulants during prospective
follow-up.
Per defect, we found similar risks of fetal loss: 1.4 (95% CI
0.3, 5.5) for the FV Leiden mutation, 1.5 (95%CI 0.2, 12.9) for
protein S deﬁciency, 1.5 (95% CI 0.3, 7.9) for protein C
deﬁciency and 1.6 (0.3, 14.0) for antithrombin deﬁciency.
Previously, we found similar odds ratios for miscarriage per
type of defect: 0.9 (95% CI 0.5, 1.5) for the FV Leiden
mutation, 1.2 (95% CI 0.7, 1.9) for protein S deﬁciency, 1.4
(95%CI 0.9, 2.2) for protein C deﬁciency and 1.7 (95%CI 1.0,
2.8) for antithrombin deﬁciency [4].
Earlier retrospective studies reported similar [19,20] or higher
[10,15] risks of fetal loss in women with a deﬁciency of
antithrombin, protein S or protein C. For FV Leiden, several
previous reports showed an association with late fetal loss (2nd
and 3rd trimester) [5,6,8–11,16–18], while reports were contra-
dictory on the association with early fetal loss (1st trimester)
[5,7,9,12–14,16–18,21–24]. Discrepancies between studies could
be explained by their design: many previous reports were based
on case–control studies targeting recurrent miscarriage without
a comparison with women in the general population, which
precludes risk calculation. According to Bick et al., 55–62%
of recurrent miscarriages are caused by blood coagulation
protein or platelet defects, whereas about 90% of ﬁrst-time
miscarriages are caused by chromosomal defects [25]. In our
study most women [39/48 (81%); Table 1] had their ﬁrst fetal
loss during prospective follow-up. It may well be that
thrombophilia plays a role in a small selected group of women
with recurrent fetal loss, who are likely to have some other, as
yet unknown, defects.
We found no positive effect of thromboprophylaxis on
the outcome of a pregnancy in 21 women with thrombophilia
who used heparin or oral anticoagulants before week 5 of
pregnancy until the end of the pregnancy (relative risk 0.7; 95%
CI 0.2, 3.2). However, this group is rather small to draw solid
conclusions from and treatment in this group differed per
person in type and dose, as most women received thrombo-
prophylactic treatment during pregnancy to prevent venous
thrombosis. However, since the risk of fetal loss without
thromboprophylaxis was only mildly increased, a strong
beneﬁcial effect could not be expected in this study. In women
with a severe thrombotic tendency and recurrent fetal loss,
thromboprophylaxis may offer more beneﬁt, although cur-
rently only non-conclusive information is available on throm-
boprophylaxis for pregnant women with thrombophilia and a
history of obstetric complications [9,26–29].
In conclusion, although the risk of fetal loss is increased in
women with thrombophilia, the overall likelihood of a positive
outcome is high. Further research regarding prophylactic
treatment (heparin, oral anticoagulants or newly developed
anticoagulants) should be performed, targeting high-risk
women, weighing risks and beneﬁt. At the moment, thrombo-
phylactic treatment does not seem indicated in women without
a history of fetal loss for prevention of fetal loss only, while it
may be a worthwhile option in women with a severe
thrombotic tendency and recurrent fetal loss.
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